Type 2 diabetes is a progressive disorder characterized by continuous deterioration in beta-cell function requiring an escalation of therapeutic efforts in order to maintain glycaemic control. Recent studies have demonstrated that the current antidiabetic treatments, including metformin, sulfonylureas and thiazolidinediones, are not durable resulting in an increase of HbA1c over time with all three therapies. Many current antidiabetic treatments (sulfonylureas, thiazolidinediones and insulin) are associated by the undesirable feature of weight gain. In addition, sulfonylureas and insulin are associated with an increased risk for hypoglycaemia. The unsatisfactory results with the current pharmacological therapies for type 2 diabetes have encouraged the development of a number of novel treatments. Among these are the incretin-based therapies, which include GLP-1 receptor agonists; this review focuses on one of these agonists the human GLP-1 analogue liraglutide. Liraglutide has been approved for use in type 2 diabetic individuals in several countries, including Europe, USA and Japan.
Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes / Hribal, Ml; Sesti, G. - In: EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM. - ISSN 1744-6651. - 5:4(2010), pp. 495-505. [10.1586/eem.10.20]
Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes
SESTI G
Ultimo
Writing – Original Draft Preparation
2010
Abstract
Type 2 diabetes is a progressive disorder characterized by continuous deterioration in beta-cell function requiring an escalation of therapeutic efforts in order to maintain glycaemic control. Recent studies have demonstrated that the current antidiabetic treatments, including metformin, sulfonylureas and thiazolidinediones, are not durable resulting in an increase of HbA1c over time with all three therapies. Many current antidiabetic treatments (sulfonylureas, thiazolidinediones and insulin) are associated by the undesirable feature of weight gain. In addition, sulfonylureas and insulin are associated with an increased risk for hypoglycaemia. The unsatisfactory results with the current pharmacological therapies for type 2 diabetes have encouraged the development of a number of novel treatments. Among these are the incretin-based therapies, which include GLP-1 receptor agonists; this review focuses on one of these agonists the human GLP-1 analogue liraglutide. Liraglutide has been approved for use in type 2 diabetic individuals in several countries, including Europe, USA and Japan.File | Dimensione | Formato | |
---|---|---|---|
Hribal_Liraglutide_2010 .pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
282 kB
Formato
Adobe PDF
|
282 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.